Highlight of New Phosphodiesterase 10A Inhibitors Using Molecular Docking
Halla Belhoula1, El Hassen Mokrani1, Abderrahmane Bensegueni1 & Djihane Bioud1 Show affiliations
- University Brother Mentouri Constantine 1, United States
Current Research in Bioinformatics, Volume 8, Issue 1, pp. 34–37 · doi.org/10.3844/ajbsp.2019.34.37
Abstract
Phosphodiesterase 10A (PDE 10A) is an effective therapeutic approach for treatments of Schizophrenia (SCZ). In order to identify in silico new potent PDE 10A inhibitors, molecular docking approach was used. In this context, the compound S235 was predicted to exhibit a high potential PDE 10A inhibitory activity among 369 compounds tested. The predicted binding energy of this compound was improved from -10.28 to -13.80 Kcal/mol by structural replacements of its chemical grouping. Finally, the proposed compound was predicted to have good ADMET properties.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Belhoula, H., Mokrani, E. H., Bensegueni, A. & Bioud, D. (2019). Highlight of New Phosphodiesterase 10A Inhibitors Using Molecular Docking. Current Research in Bioinformatics, 8(1), 34–37. https://doi.org/10.3844/ajbsp.2019.34.37
- Licence
- CC BY 3.0
- Issue
- Volume 8, Issue 1
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record